Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer

Listen to this conversation between Cristina Saura Manich, MD, PhD, and Giampaolo Bianchini, MD, as they discuss practical approaches to PI3K pathway testing, emerging PI3K and AKT-targeted treatment options, and sequencing therapy for patients with metastatic breast cancer following development of endocrine therapy resistance.